**Core tip:** This is a retrospective study that evaluated the clinical and prognostic significance of the preoperative (pre-) and postoperative (post-) mRNA levels of cytokeratin 19 (CK19) and carcinoembryonic antigen (CEA) in peripheral blood of patients with gastric cardia cancer. Increased pre- and post-CK19 and CEA mRNA levels were associated with positive lymph node metastasis. Elevated pre- but not post-CK19 and CEA mRNA levels were independent prognostic factors for overall survival (OS). A new prognostic model was established based on independent prognostic factors (lymph node status, pre-CK19 and pre-CEA mRNA levels), and there was a significant difference in OS among the three different risk groups.

INTRODUCTION
============

Gastric cancer (GC) is the third leading cause of cancer-related death worldwide\[[@B1]\]. Recently, the incidence of gastric cardia cancer (GCC) has increased around the world\[[@B2],[@B3]\]. The prognosis of patients with GCC was worse than that of patients with non-cardiac GC\[[@B4]\]. Although the important advances in surgical techniques and adjuvant chemotherapies have improved patient outcomes, the 5-year survival rate remains low (10%-30%)\[[@B5]\]. Metastasis and recurrence after surgery are the main causes of treatment failure and poor prognosis\[[@B6]\]. Therefore, it is of great significance to establish molecular biomarkers for GCC to detect early metastasis and improve survival.

Carcinoembryonic antigen (CEA), one of the most commonly used serum tumor markers in GC, plays an important role in tumor metastasis and may be partially associated with prognosis in GC\[[@B7]\]. Cytokeratin 19 (CK19), which originates from epithelial cells, is a reliable tissue-specific marker for epithelial tumor micrometastasis and is highly expressed in the gastrointestinal tract but not in normal lymph node tissue or blood. The detection of CEA and CK19 expression has been used to examine tumor micrometastasis and predict the prognosis in GC and esophageal squamous cell carcinoma\[[@B8],[@B9]\]. Nevertheless, there is no valid marker to predict the lymph node metastasis and prognosis in patients with GCC. Recently, quantitative real-time polymerase chain reaction (qRT-PCR) technology, a sensitive, specific and rapid method, has been widely used to detect the presence of circulating cancer cells in peripheral blood, the expression of tumor markers, and micrometastases, as well as predict prognoses\[[@B10]\]. However, there are few reports on the detection and clinical significance of CEA and CK19 mRNAs in the peripheral blood of GCC patients. With the decrease in tumor burden after surgery, the levels of tumor marker expression will change. Some studies have supported the use of preoperative (pre-) CEA levels as prognostic markers in GC\[[@B11],[@B12]\], whereas other studies have reported the prognostic value of postoperative (post-) CEA levels\[[@B13]\]. There are limited data regarding the prognostic significance of pre- and post-CK19 levels in GCC.

In the present study, we detected the pre- and post-CEA and CK19 mRNA levels in peripheral blood of patients with GCC by using qRT-PCR and estimated the clinical and prognostic value of these biomarkers in patients with GCC.

MATERIALS AND METHODS
=====================

Patients and peripheral blood sample collection
-----------------------------------------------

A total of 129 patients who were diagnosed with GCC and underwent curative surgery between January 2009 and December 2011 at Tianjin Medical University Cancer Institute and Hospital were recruited for the study. The inclusion criteria of the study were as follows: (1) complete clinicopathological and follow-up data; (2) no neoadjuvant chemotherapy, radiotherapy or chemoradiotherapy; (3) radical gastrectomy for the primary tumor and D2 lymph node dissection following the Japanese Research Society for Gastric Cancer guidelines\[[@B14]\]; (4) no gross or microscopic residual or recurrent gastric tumor; (5) no distant metastases prior to surgery; and (6) no other synchronous malignancies. The histological diagnosis and tumor-node-metastasis (TNM) staging were based on 7^th^ edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) TNM staging system\[[@B15]\]. The study and acquisition of blood specimens were approved by the Research Ethics Committee of Tianjin Medical University Cancer Institute and Hospital. In addition, all of the patients provided written informed consent.

Total RNA isolation and cDNA synthesis
--------------------------------------

Three to five millilambert peripheral blood samples were obtained through a catheter inserted into a peripheral vessel and collected into EDTA tubes from each GCC patient before and after surgical resection. Sample processing was performed within 2 h after blood collection. Karyocytes were isolated from the blood samples using a lymphocyte separation medium according to the manufacturer's instructions (Solarbio, Beijing, China). Briefly, blood samples were subjected to Ficoll-sodium diatrizoate density gradient centrifugation. Then, after discarding the plasma layer, the samples were mixed with a wash buffer and centrifuged at 200 *g* for 10 min. The pelleted cells were resuspended in red blood cell lysis buffer (Solarbio) and centrifuged another two times. The remaining cells, which are karyocytes in PB, were washed with PBS, and the total cellular RNA isolation and cDNA synthesis were performed as previously described\[[@B9]\]. Total RNA was extracted from the cell lysate using TRIzol reagent (Invitrogen, Gaithersburg, MD, United States) according to the manufacturer's instructions. The concentration and purity of RNA were determined by using a NanoDrop spectrophotometer (Thermo Scientific, Wilmington, DE, United States). A260/A280 ratios in the range of 1.8 to 2.0 were considered satisfactory for purity standards in this study. First-strand cDNA was synthesized using the SuperScript First-Strand cDNA Synthesis kit (Invitrogen) according to the manufacturer's instructions and then stored at -20 °C for subsequent quantitative polymerase chain reaction experiments.

Real-time PCR
-------------

The mRNA expression levels of CK19 and CEA were detected by real-time PCR using the ABI 7500 Real-Time PCR system (Applied Biosystems, Foster City, CA, United States). Glyceraldehyde-3-phosphatedehydrogenase (GADPH) was amplified as an internal control to correct for differences in the amount of total RNA per sample by normalizing the mRNA levels of CK19 and CEA to the corresponding GAPDH levels. The relative levels of the normalized gene expression were calculated with the equation 2^-ΔCT^, in which ΔCT = CT gene- CT control. All of the reactions were run in triplicate. The primers targeting CK19, CEA and GAPDH were as follows: 5'-ATGAAAGCTGCCTTGGAAGA-3' (CK19, forward) and 5'-TGATTCTGC- CGCTCACTATCAG-3' (CK19, reverse); 5'-AACTGGTGT- CCCGGATATCA-3' (CEA, forward) and 5'-ATATTCTTTGCTCCTTGCCA-3' (CEA, reverse); 5′-AGAAGGCTGGGGCTCATTTG-3′ (GAPDH, forward) and 5′-AGGGGCCATCCACAGTCTTC-3′ (GAPDH, reverse). The following thermocycling conditions were used under the standard mode according to the manufacturer's recommendations: 30 s at 95 °C followed by 40 cycles of 95 °C for 5 s and 60 °C for 34 s.

Follow-up
---------

After curative resection, all patients were followed regularly every 3 mo during the first two years, every 6 mo during the third to fifth years, and every 1 year thereafter until death or the last follow-up. Postoperative follow-up observations involved physical examinations, laboratory blood tests, tumor markers, chest radiography, abdominal computed tomography scan, and endoscopy examinations. The final follow-up date was December 2015. Overall survival (OS) was calculated from the date of surgery to death or the final follow-up date.

Statistical analysis
--------------------

All statistical analyses were performed using SPSS 17.0 statistical software (SPSS Inc, Chicago, IL, United States). The receiver operating characteristic (ROC) curves were plotted to determine the optimal cutoff points for pre- and post-CK19 and CEA mRNA levels in predicting 5-year survival. Interdependence between the CK19 mRNA levels, CEA mRNA levels, and clinical data were calculated using the *χ*^2^ test and are displayed in cross-tables. Survival analysis was performed using the Kaplan-Meier method and compared by the log-rank test. The variables significantly affecting OS were investigated by multivariate analysis according to the Cox proportional hazard model. *P* values \< 0.05 were considered statistically significant.

RESULTS
=======

Patients and characteristics
----------------------------

A total of 129 patients with GCC were included in our study. There were 27 (20.9%) females and 102 (79.1%) males, and the median age was 61 years (range, 38-84 years). All patients were histologically confirmed with adenocarcinoma after surgery. According to the histopathological grading, well and moderately differentiated tumors were observed in 99 (76.7%) patients, and 30 (23.3%) patients presented poorly differentiated or undifferentiated tumors. Based on the criteria of the 7^th^ edition of the UICC/AJCC TNM staging system, 34 (26.4%) and 95 (73.6%) patients had T1-T2 and T3-4 disease, respectively. Postoperative histological examinations confirmed that lymph node metastasis was present in 51 (39.5%) cases. With regard to the TNM stage, 11 (8.5%) cases were subsequently diagnosed with stage I, 75 (58.1%) with stage II, and 43 (33.3%) with stage III.

Correlation between the pre- and post-CK19 mRNA levels and clinicopathological factors
--------------------------------------------------------------------------------------

According to the ROC curve shown in Figure [1](#F1){ref-type="fig"}, the cutoff values of the pre- and post-CK19 mRNA levels were set at 55.0 and 53.6, respectively. Based on these cutoff values in predicting 5-year survival, the sensitivity and specificity were 69.7% and 69.8%, respectively, for pre-CK19 mRNA, and 57.9% and 58.5%, respectively, for post-CK19 mRNA. The corresponding areas under the curve (AUCs) were 0.712 and 0.610, respectively. Thus, we divided the patients into "low pre-CK19" (\< 55.0, *n* = 63) and "high pre-CK19" (\> 55.0, *n* = 66) groups as well as "low post-CK19" (\< 53.6, *n* = 67) and "high post-CK19" (\> 53.6, *n* = 62) groups.

![Receiver operating characteristic curves for preoperative and postoperative cytokeratin 19 and carcinoembryonic antigen mRNA levels in patients with gastric cardia cancer according to overall survival. A: Preoperative CK19 mRNA level; B: Postoperative CK19 mRNA level; C: Preoperative CEA mRNA level; D: Postoperative CEA mRNA level. AUC: Area under the curve; CK19: Cytokeratin 19; CEA: Carcinoembryonic antigen; ROC: Receiver operating characteristic.](WJG-23-1424-g001){#F1}

The correlations between the pre- and post-CK19 mRNA levels and the clinicopathological characteristics are shown in Table [1](#T1){ref-type="table"}. The pre-CK19 mRNA levels were significantly correlated with tumor size (*P* = 0.008), lymph node status (*P* = 0.033), and TNM stage (*P* = 0.012), but showed no significant correlations with other measured clinicopathological characteristics (*P* \> 0.05 for all). Furthermore, the post-CK19 mRNA levels were only correlated with lymph node status (*P* = 0.048) and not with any other clinicopathological characteristics measured (*P* \> 0.05 for all).

###### 

Correlation between the preoperative and postoperative cytokeratin 19 mRNA levels and the clinicopathological features of 129 patients with gastric cardia cancer *n* (%)

  **Clinicopathological feature**          **Cases**   **CK19 mRNA level (pre-)**   ***χ*^2^ test**   **CK19 mRNA level (post-)**   ***χ*^2^ test**                                   
  ---------------------------------------- ----------- ---------------------------- ----------------- ----------------------------- ----------------- ----------- ----------- ------- -------
  Gender                                                                                              1.484                         0.223                                     1.663   0.197
  Male                                     102         47 (46.1)                    55 (53.9)                                                         50 (49.0)   52 (51.0)           
  Female                                   27          16 (59.3)                    11 (40.7)                                                         17 (63.0)   10 (37.0)           
  Age (yr)                                                                                            0.411                         0.521                                     0.052   0.820
  ≤ 60                                     59          27 (45.8)                    32 (54.2)                                                         30 (50.8)   29 (49.2)           
  \> 60                                    70          36 (51.4)                    34 (48.6)                                                         37 (52.9)   33 (47.1)           
  Tumor size (cm)                                                                                     6.928                         0.008                                     3.250   0.071
  ≤ 4                                      75          44 (58.7)                    31 (41.3)                                                         44 (58.7)   31 (41.3)           
  \> 4                                     54          19 (35.2)                    35 (64.8)                                                         23 (42.6)   31 (57.4)           
  Histological grade                                                                                  0.474                         0.491                                     0.030   0.861
  Well/moderately differentiated           99          50 (50.5)                    49 (49.5)                                                         51 (51.5)   48 (48.5)           
  Poorly differentiated/undifferentiated   30          13 (43.3)                    17 (6.7)                                                          16 (53.3)   14 (46.7)           
  Depth of tumor invasion                                                                             3.088                         0.079                                     3.015   0.082
  T1-T2                                    34          21 (61.8)                    13 (38.2)                                                         22 (64.7)   12 (35.3)           
  T3-T4                                    95          42 (44.2)                    53 (55.8)                                                         45 (47.4)   50 (52.6)           
  Lymph node status                                                                                   4.528                         0.033                                     3.913   0.048
  Negative                                 78          44 (56.4)                    34 (43.6)                                                         46 (59.0)   32 (41.0)           
  Positive                                 51          19 (37.3)                    32 (62.7)                                                         21 (41.2)   30 (58.8)           
  TNM stage                                                                                           8.861                         0.012                                     2.848   0.241
  I                                        11          9 (81.8)                     2 (18.2)                                                          7 (63.6)    4 (36.4)            
  II                                       75          39 (52.0)                    36 (48.0)                                                         42 (56.0)   33 (44.0)           
  III                                      43          15 (34.9)                    28 (65.1)                                                         18 (41.9)   25 (58.1)           

CK19: Cytokeratin 19.

Correlation between the pre- and post-CEA mRNA levels and clinicopathological factors
-------------------------------------------------------------------------------------

According to the plotted ROC curves (Figure [1C](#F1){ref-type="fig"} and D), the optimal cutoff values of the pre- and post-CEA mRNA levels were set at 9.3 and 8.8, respectively. Based on these cutoff values in predicting 5-year survival, the sensitivity and specificity were 72.4% and 59.7%, respectively, for pre-CEA mRNA, and 67.1% and 54.7%, respectively, for post-CEA mRNA. The AUCs were 0.753 and 0.666, respectively. Thus, we divided the patients into "low pre-CEA" (\< 9.3, *n* = 52) and "high pre-CEA" (\> 9.3, *n* = 77) groups as well as "low post-CEA" (\< 8.8, *n* = 69) and "high post-CEA" (\> 8.8, *n* = 70) groups.

The associations between the pre- and post CEA mRNA levels and the clinicopathological characteristics are shown in Table [2](#T2){ref-type="table"}. Pre-CEA mRNA levels were closely correlated with tumor size (*P* = 0.031), lymph node status (*P* = 0.002), and TNM stage (*P* = 0.048). However, no statistical significance was observed in the correlation between pre- CEA mRNA levels and the other measured clinicopathological features (*P* \> 0.05 for all). Furthermore, there was a significant correlation between post-CEA mRNA levels and tumor size (*P* = 0.016), lymph node status (*P* = 0.008), and TNM stage (*P* = 0.025), but no statistical significance was observed in the correlation between post-CEA mRNA levels and the other measured clinicopathological features (*P* \> 0.05 for all).

###### 

Correlation between the preoperative and postoperative carcinoembryonic antigen mRNA levels and clinicopathological features in 129 patients with gastric cardia cancer *n* (%)

  **Clinicopathological feature**          **Cases**   ***CEA* mRNA level (pre-)**   ***χ*^2^ test**   ***CEA* mRNA level (post-)**   ***χ*^2^ test**                                   
  ---------------------------------------- ----------- ----------------------------- ----------------- ------------------------------ ----------------- ----------- ----------- ------- -------
  Gender                                                                                               1.891                          0.169                                     1.327   0.249
  Male                                     102         38 (37.3)                     64 (62.7)                                                          44 (43.1)   58 (56.9)           
  Female                                   27          14 (51.9)                     13 (48.1)                                                          15 (55.6)   12 (44.4)           
  Age (yr)                                                                                             0.413                          0.521                                     1.121   0.290
  ≤ 60                                     59          22 (37.3)                     37 (62.7)                                                          24 (40.7)   35 (59.3)           
  \> 60                                    70          30 (42.9)                     40 (57.1)                                                          35 (50.0)   35 (50.0)           
  Tumor size (cm)                                                                                      0.078                          0.780                                     5.757   0.016
  ≤ 4                                      75          31 (41.3)                     44 (58.7)                                                          41 (54.7)   34 (45.3)           
  \> 4                                     54          21 (38.9)                     33 (61.1)                                                          18 (33.3)   36 (66.7)           
  Histological grade                                                                                   3.024                          0.082                                     2.423   0.12
  Well/moderately differentiated           99          44 (44.4)                     55 (55.6)                                                          49 (49.5)   50 (50.5)           
  Poorly differentiated/undifferentiated   30          8 (26.7)                      22 (73.3)                                                          10 (33.3)   20 (66.7)           
  Depth of tumor invasion                                                                              4.653                          0.031                                     0.966   0.326
  T1-T2                                    34          19 (55.9)                     15 (44.1)                                                          18 (52.9)   16 (47.1)           
  T3-T4                                    95          33 (34.7)                     62 (65.3)                                                          41 (43.2)   54 (56.8)           
  Lymph node status                                                                                    9.871                          0.002                                     7.012   0.008
  Negative                                 78          40 (51.3)                     38 (48.7)                                                          43 (55.1)   35 (44.9)           
  Positive                                 51          12 (23.5)                     39 (76.5)                                                          16 (31.4)   35 (68.6)           
  TNM stage                                                                                            6.063                          0.048                                     7.379   0.025
  I                                        11          6 (54.5)                      5 (45.5)                                                           9 (81.8)    2 (18.2)            
  II                                       75          35 (46.7)                     40 (53.3)                                                          34 (45.3)   41 (54.7)           
  III                                      43          11 (25.6)                     32 (74.4)                                                          16 (37.2)   27 (62.8)           

CK19: Cytokeratin 19; CEA: Carcinoembryonic antigen; TNM: Tumor-node-metastasis.

Univariate and multivariate survival analyses of clinicopathological characteristics for OS of patients with GCC
----------------------------------------------------------------------------------------------------------------

The median follow-up period for the entire cohort was 42 mo (range, 6-84 mo). The 5-year OS rate for all the patients was 31.7% with a median survival time of 39 mo.

The 5-year OS curves of patients based on the pre- and post-CK19 mRNA and CEA mRNA levels are shown in Figure [2](#F2){ref-type="fig"}. The 5-year OS rates for the low pre-CK19 and high pre-CK19 groups were 42.1% and 21.5%, respectively (*χ*^2^ = 9.183, *P* = 0.002; Figure [2A](#F2){ref-type="fig"}). The 5-year OS rates for low post-CK19 and high post-CK19 groups were 36.5% and 27.4%, respectively (*χ*^2^ = 2.773, *P* = 0.096; Figure [2B](#F2){ref-type="fig"}). The 5-year OS rates for low pre-CEA and high pre-CEA groups were 52.2% and 19.5%, respectively (*χ*^2^ = 12.890, *P* = 0.000, Figure [2C](#F2){ref-type="fig"}). The 5-year OS rates for low post-CEA and high post-CEA groups were 39.5% and 25.4%, respectively (*χ*^2^ = 4.721, *P* = 0.030; Figure [2D](#F2){ref-type="fig"}).

![Kaplan-Meier survival curves according to preoperative and postoperative cytokeratin 19 and carcinoembryonic antigen mRNA levels in patients with gastric cardia cancer. A: Preoperative CK19 mRNA level; B: Postoperative CK19 mRNA level; C: Preoperative CEA mRNA level; D: Postoperative CEA mRNA level. *P* values were calculated by the log-rank test and *P* \< 0.05 denoted significance. OS: Overall survival; CK19: Cytokeratin 19; CEA: Carcinoembryonic antigen.](WJG-23-1424-g002){#F2}

Univariate Kaplan-Meier analysis showed that tumor size (*P* = 0.015), histological grade (*P* = 0.039), depth of tumor invasion (*P* = 0.010), lymph node status (*P* \< 0.001), pre-CK19 mRNA level (*P* = 0.002), pre-CEA mRNA level (*P* \< 0.001), and post-CEA mRNA level (*P* = 0.030) significantly affected the prognosis of patients with GCC (Table [3](#T3){ref-type="table"}).

###### 

Univariate and multivariate analyses of the clinicopathological variables for overall survival in 129 patients with gastric cardia cancer

  **Clinicopathological feature**   **Univariate analysis**   **Multivariate analysis**                         
  --------------------------------- ------------------------- --------------------------- --------------------- -------
  Gender                            1.377 (0.797-2.377)       0.245                                             
  Age (yr)                          0.812 (0.529-1.247)       0.336                                             
  Tumor size(cm)                    1.688 (1.097-2.596)       0.015                       1.305 (0.816-2.089)   0.267
  Histological grade                1.277 (1.008-1.619)       0.039                       1.104 (0.860-1.418)   0.436
  Depth of tumor invasion           1.985 (1.162-3.393)       0.010                       1.191 (0.660-2.151)   0.562
  Lymph node status                 2.894 (1.864-4.492)       0.000                       1.848 (1.109-3.079)   0.018
  Pre-CK19 mRNA                     1.932 (1.247-2.992)       0.002                       1.625 (1.035-2.553)   0.035
  Post-CK19 mRNA                    1.431 (0.932-2.197)       0.096                                             
  Pre-CEA mRNA                      2.337 (1.443-3.784)       0.000                       1.918 (1.162-3.166)   0.011
  Post-CEA mRNA                     1.609 (1.039-2.492)       0.030                       1.213 (0.753-1.955)   0.427

CK19: Cytokeratin 19; CEA: Carcinoembryonic antigen; HR: Hazard ratio.

The seven factors with prognostic potential for OS were subsequently subjected to multivariate analysis using the Cox proportional hazards model. As shown in the Table [3](#T3){ref-type="table"}, the multivariate survival analysis indicated that lymph node status (*P* = 0.018), pre-CK19 mRNA levels (*P* = 0.035), and pre-CEA mRNA levels (*P* = 0.011) were independent prognostic factors for patients with GCC.

Prognostic model and risk groups
--------------------------------

To better identify GCC patients at high risk for lymph node metastasis and poor OS, we proposed a new prognostic model by combining the three identified independent prognostic factors and stratified patients into three groups as follows: the low-risk group, comprising patients with 0 or 1 risk factor; the intermediate-risk group, comprising patients with 2 factors; and the high-risk group, comprising patients with all 3 factors. Finally, there were 57, 34, and 26 patients in the low-, intermediate-, and high-risk groups, respectively. The 5-year OS rates for the low-, intermediate-, and high-risk groups were 48.3%, 22.6%, and 4.6%, respectively, and a statistically significant difference was observed (*χ*^2^ = 28.319, *P* \< 0.001; Figure [3](#F3){ref-type="fig"}).

![Cumulative survival curves for 129 patients with gastric cardia cancer according to risk groups by Kaplan-Meier survival analysis. The 5-year OS rates for the low-, intermediate-, and high-risk groups were 48.3%, 22.6% and 4.6%, respectively (*P* \< 0.001). OS: Overall survival.](WJG-23-1424-g003){#F3}

DISCUSSION
==========

Invasion and distant metastasis are the leading factors influencing the clinical outcome of patients with GC\[[@B16]\]. Many GC patients with resectable tumors died of postoperative distant metastasis and had a poor prognosis. GCC has been reported to be a distinct clinical entity based on its pathogenesis and risk factors and has a higher incidence of lymph node metastasis and a poorer prognosis than non-cardiac GC\[[@B17],[@B18]\]. Therefore, identifying one method or marker to determine the potential of cancer cell spreading and disease progression in patients with GCC will certainly help to tailor postoperative adjuvant therapies and improve clinical outcomes. However, there are no markers available that can predict lymph node metastasis and evaluate the prognosis of patients with GCC.

Numerous factors are associated with patient prognosis, including the expression of growth factors and their receptors, cell cycle regulators, cell adhesion molecules and matrix-degrading enzymes, all of which play important roles in tumor cell proliferation, invasion, and metastasis\[[@B19]\]. For GC, several tumor-specific markers, including CEA and CK19 in either serum or tumor tissue (as evaluated by either enzyme immunoassay kit or immunohistochemistry, respectively), have been used to detect metastasis and predict prognosis\[[@B8],[@B11]\]. Recently, qRT-PCR has been shown to have a sensitivity 10- to 100-fold higher than the routine immunological methods and to be a reliable method for detecting circulating tumor cells, measuring the mRNA expression of tumor markers, and predicting patient prognosis\[[@B10]\]. In addition, compared with the acquisition of bone marrow, lymph nodes or tumor tissues, peripheral blood collection is a minimally invasive procedure and can be collected throughout the entire disease process\[[@B6]\]. All these data have garnered increasing attention in this field of research to analyze the clinical and prognostic value of CEA and CK19 mRNAs in the peripheral blood of GCC patients by using qRT-PCR.

In the present study, we detected the CK19 and CEA mRNA levels in peripheral blood of GCC patients by using qRT-PCR and analyzed the correlation between CK19 and CEA mRNA levels with clinicopathological variables. Our results showed significant correlations between the pre-CK19 mRNA levels and tumor size, lymph node status, and TNM stage as well as between the pre-CEA mRNA levels and T status, lymph node status, and TNM stage. Furthermore, a significant association could be found between post-CEA mRNA levels and tumor size, lymph node status, and TNM stage. However, the post-CK19 mRNA levels were only correlated with lymph node status. These results indicated that pre- and post-CEA mRNA and CK19 mRNA levels had different clinical values in GCC, and it seems that pre-CEA and CK19 mRNA levels may have a stronger prognostic role than post-CEA and CK19 mRNA levels. During disease progression, tumor cells lose their intercellular adhesion molecules, and unpredictable lymphatic spread can occur. Lymph node metastasis is one of the most important prognostic factors for GCC. However, it is difficult to detect lymph node micrometastasis by routine pathological examination\[[@B8]\]. In the present study, our results showed that both pre- and post-CEA mRNA levels as well as pre- and post-CK19 mRNA levels were associated with positive lymph node metastasis. Our results was similar to the reports by Yanagita et al\[[@B20]\] and Kochi et al\[[@B11]\], who demonstrated that CK19 and CEA mRNA levels in peripheral blood were correlated with lymph node metastasis in GC. CK19, a cytoskeletal protein, is exclusively expressed in epithelial tissues and any tumor tissues derived from the epithelium. If the CK19 transcript is detected in lymph nodes of patients with epithelial tumors, the presence of disseminated cancer cells could be considered\[[@B21]\]. Therefore, our results indicated that both CEA mRNA and CK19 mRNA levels may serve as potential markers to detect lymph node metastasis in GCC.

Previous studies have suggested the potential role of CEA in monitoring disease recurrence and treatment response as well as in predicting the prognosis of many malignancies\[[@B22]-[@B24]\]. Cytokeratins are components of epithelial cells and the intermediate filaments of epithelial cancer cells; these proteins are involved in the dynamic remodeling of tumor cells during invasion and metastasis. CK19, a tissue-specific marker for epithelial tumor micrometastasis, has been reported to be a prognostic marker in esophageal cancer\[[@B9]\], hepatocellular carcinoma\[[@B25]\], and lung cancer\[[@B21]\]. Based on the previously published data of CEA and CK19 in other malignancies, we further explored the relationships between pre- and post-CEA and CK19 mRNA levels with OS in patients with GCC. To analyze the prognostic value of pre- and post-CEA and CK19 mRNA levels in GCC, Kaplan-Meier survival analysis and multivariate analysis were performed in the following analysis. The Kaplan-Meier survival analysis showed that both pre- and post-CEA mRNA levels as well as elevated pre-CK19 mRNA levels (but not post-CK19 mRNA levels) were correlated with a poor prognosis in GCC. In addition, the current study showed that the rate of elevated pre-CEA mRNA expression was 59.6%, which was higher than the rate of increased pre-CK19 mRNA expression (51.2%). These results indicated that CEA mRNA levels in peripheral blood of GCC patients may have a stronger prognostic prediction power than CK19 mRNA and that CEA mRNA levels seem to be a potential marker with a high sensitivity for prognostic prediction. Our observation was similar to that from a study by Ikeguchi et al\[[@B26]\], who proposed that CEA was more reliable than cytokeratins in detecting disseminated tumor cells. Multivariate analysis further showed that lymph node status, pre-CK19 mRNA levels and pre-CEA mRNA levels negatively affected the prognosis of GCC patients. These data indicate that pre-CK19 and CEA mRNA levels in peripheral blood of GCC patients who underwent a radical gastrectomy are more accurate indicators of prognosis than post-CK19 and CEA mRNA levels. One reason may be because the levels of CK19 and CEA mRNAs are proportional to the tumor load and TNM stage, and the CK19 and CEA mRNA levels will inevitably decrease after tumor removal. Thus, the pre-CK19 and CEA mRNA levels may have a stronger power to reflect the entire status of disease and predict prognosis compared with post-CK19 and CEA mRNA levels.

In clinical practice, we noticed that GCC patients with three independent risk factors (positive lymph node metastasis, elevated pre-CK19 and CEA mRNA levels) tended to have a poorer prognosis. Therefore, we proposed a prognostic model based on these three risk factors and classified GCC patients into low-, intermediate- and high-risk groups. We further compared the survival curves of the three groups and found that there was a significant difference in OS among the three different risk groups. This prognostic model can be easily constructed and may potentially help clinicians make a more accurate judgment for prognosis and individual therapeutic treatment to improve survival and quality of life based on the risk stratification. GCC patients with a high-risk score may benefit from closer monitoring or more aggressive postoperative adjuvant therapy.

In conclusion, to the best of our knowledge, this is the first report showing that both elevated CK19 and CEA mRNA levels are correlated with positive lymph node metastasis in GCC. Elevated pre-CK19 and CEA mRNA levels were independently associated with poor prognosis in GCC patients undergoing curative surgery. Additionally, the new proposed prognostic model may help clinicians provide better individual therapeutic approaches and improve the outcome of patients with GCC based on the TNM stage.
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COMMENTS
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Background
----------

Gastric cardia cancer (GCC) is a distinct clinical entity, with a higher incidence of lymph node metastasis and poor prognosis. Meanwhile, there is no valid marker to predict the lymph node metastasis and prognosis in GCC. Carcinoembryonic antigen (CEA) and cytokeratin 19 (CK19) are related to lymph node metastasis and prognosis in gastrointestinal tumors. The level of tumor marker expression will change after surgery. Real-time polymerase chain reaction (qRT-PCR) technology, a sensitive, specific and rapid method, has been widely used to detect the expression of tumor markers. However, the clinical and prognostic significance of CEA and CK19 mRNAs in GCC patients has been few reported.

Research frontiers
------------------

Recent studies have reported that pre- or post-CEA and CK19 mRNA levels are correlated with lymph node metastasis and prognosis in gastric cancer. However, few studies have reported and compared the clinical and prognostic significance of pre- and post-CEA and CK19 mRNA levels in GCC.

Innovations and breakthroughs
-----------------------------

qRT-PCR, a sensitive, specific and rapid method, was used to detect the expression of CEA and CK19 mRNAs in GCC. In addition, this study is the first to report and compare the clinical and prognostic significance of pre- and post-CEA and CK19 mRNA levels in GCC.

Applications
------------

These results provide evidence that either pre- and post-CEA or pre- and post-CK19 mRNA levels could help predict lymph node metastasis in patients with GCC, and the prognostic value of pre-CEA and pre-CK19 mRNA levels supersedes that of post-CEA and post-CK19 mRNA levels for clinical applications.

Terminology
-----------

CK19, a cytoskeletal protein, is exclusively expressed in epithelial tissues and any tumor tissues derived from the epithelium. CEA is a glycoprotein found in epithelial cells of colon cancer and colonic mucosa.
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